Skip to main content

13 Result(s)

within Elihu H. Estey Remove this filter Internal Medicine Remove this filter

and

  1. No Access

    Article

    Clinical evaluation of complete remission (CR) with partial hematologic recovery (CRh) in acute myeloid leukemia: a report of 7235 patients from seven cohorts

    Jacob S. Appelbaum, Andrew H. Wei, Sumithra J. Mandrekar, Ing S. Tiong… in Leukemia (2024)

  2. Article

    Open Access

    Prognostic impact of secondary versus de novo ontogeny in acute myeloid leukemia is accounted for by the European LeukemiaNet 2022 risk classification

    Secondary AML (sAML), defined by either history of antecedent hematologic disease (AHD) or prior genotoxic therapy (tAML), is classically regarded as having worse prognosis than de novo disease (dnAML). Clinic...

    Michael J. Hochman, Megan Othus, Robert P. Hasserjian, Alex Ambinder… in Leukemia (2023)

    Download PDF (512 KB) View Article

  3. Article

    Open Access

    Effect of ECOG performance status on outcomes in patients with acute myeloid leukemia and other high-grade myeloid neoplasms

    Gabrielle Paras, Megan Othus, Kelda Schonhoff, Carole Shaw, Mohamed Sorror… in Leukemia (2023)

    Download PDF (529 KB) View Article

  4. No Access

    Article

    Evaluating concordance in assessment of ECOG performance status in acute myeloid leukemia patients

    Nicole Mostofi, Carole Shaw, Roland B. Walter, Mary-Elizabeth M. Percival… in Leukemia (2022)

  5. No Access

    Article

    Physician and patient perceptions on randomization of treatment intensity for unfit adults with acute myeloid leukemia and other high-grade myeloid neoplasm

    Anna B. Halpern, Megan Othus, Genevieve Alcorn, Zahra Ali… in Leukemia (2022)

  6. No Access

    Article

    Outcomes based on treatment setting in refractory acute myeloid leukemia and other high-grade myeloid malignancies

    Noam E. Kopmar, Megan Othus, Kelda M. Gardner, Carole Shaw, Anna B. Halpern… in Leukemia (2022)

  7. No Access

    Article

    Optimal dosing of cytarabine in induction and post-remission therapy of acute myeloid leukemia

    Roland B. Walter, Frederick R. Appelbaum, Elihu H. Estey in Leukemia (2021)

  8. No Access

    Article

    Need for routine examination of left ventricular ejection fraction in patients with AML

    Hiba M. Khan, Kelda M. Gardner, Carole Shaw, Anna B. Halpern, Emily M. Huebner… in Leukemia (2020)

  9. No Access

    Article

    Early achievement of measurable residual disease (MRD)-negative complete remission as predictor of outcome after myeloablative allogeneic hematopoietic cell transplantation in acute myeloid leukemia

    Alexander P. Hoffmann, Ashley L. Besch, Megan Othus… in Bone Marrow Transplantation (2020)

  10. No Access

    Article

    Early hospital discharge after intensive induction chemotherapy for adults with acute myeloid leukemia or other high-grade myeloid neoplasm

    Anna B. Halpern, Nicholas P. Howard, Megan Othus, Paul C. Hendrie… in Leukemia (2020)

  11. No Access

    Article

    Second cycle remission achievement with 7+3 and survival in adults with newly diagnosed acute myeloid leukemia: analysis of recent SWOG trials

    Megan Othus, Elihu H. Estey, Guillermo Garcia-Manero, Brent L. Wood… in Leukemia (2019)

  12. No Access

    Article

    Phase 1/2 trial of GCLAM with dose-escalated mitoxantrone for newly diagnosed AML or other high-grade myeloid neoplasms

    Outcomes with “7 + 3” are often unsatisfactory in acute myeloid leukemia (AML). Trials demonstrating improved outcomes with high-dose cytarabine, addition of cladribine, or escalated anthracycline doses prompt...

    Anna B. Halpern, Megan Othus, Emily M. Huebner, Bart L. Scott, Pamela S. Becker… in Leukemia (2018)

  13. Article

    New drugs in AML: uses and abuses

    Elihu H. Estey, Robert Peter Gale, Mikkael A. Sekeres in Leukemia (2018)

    Download PDF (243 KB) View Article